Jan. 27, 2026 – Today Skyhawk Therapeutics Inc. announced encouraging interim results concerning SKY-0515, an investigational medicine being studied for Huntington disease (HD).
These results are from the Phase 1 trial. There are not currently any Canadian study sites. The next step is the Phase 2/3 FALCON-HD study, which is currently enrolling participants in Australia, New Zealand, and Georgia. Other countries will be added soon.
Resources
To read Skyhawk’s community letter, click here: https://hsc.huntingtonsociety.ca/public/commmunity-letter/skyhawk-jan-2026.pdf
To read Skyhawk’s press release, click here: https://hsc.huntingtonsociety.ca/public/press-release/skyhawk-jan-2026.pdf
More details are available at ClinicalTrials.gov and www.FALCON-HD.com
If you would like to connect with a member of the Family Services team, please reach out to your RCD or, if you’re new to HSC, please fill out our online form: https://contactme.cloud/form/huntingtonsociety
Staying Connected
Staying connected with HSC is the best way to make sure you hear about new research opportunities and updates. Please sign up for our e-newsletters here: www.huntingtonsociety.ca/enewsletters/. You can also follow HSC on our social media: Facebook, Instagram, and LinkedIn.